Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNTY-101 + IL-2
- Development stage
- Unknown
- Lead developer
- Century Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
CNTY-101 + IL-2 is an investigational combination therapy comprising CNTY-101, an allogeneic iPSC-derived anti-CD19 chimeric antigen receptor natural killer (CAR-iNK) cell therapy, and recombinant human interleukin-2 (IL-2), a cytokine. CNTY-101 incorporates six precision gene edits (including CD19-CAR, Allo-Evasion edits to prevent host immune rejection, and IL-15 cytokine support), designed for enhanced persistence and anti-tumor activity. The co-administration of IL-2 provides exogenous cytokine support to promote expansion and activation of infused NK cells. This combination is being evaluated in phase 1 clinical trials both for relapsed/refractory CD19-positive B-cell malignancies (such as diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma) and for severe autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and diffuse cutaneous systemic sclerosis[1][2][3][4][5].
- Other names
- CNTY-101 plus interleukin-2CNTY101 plus interleukin-2CNTY 101 plus interleukin-2CNTY-101 and IL-2CNTY101 and IL-2CNTY 101 and IL-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)CD19 (B lymphocyte antigen CD19)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on CNTY-101 + IL-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNTY-101 + IL-2.